Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib adherence and response in chronic myeloid leukemia
NL-OMON23279Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Vrije University Medical Center. Primary endpoints: Major molecular response within 12 months and Adherence by medication event monitoring system. Started Aug 2013; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON23279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23279.